Adversarial Injection · Revumenib (Revuforj; SNDX-5613; CAS 2097129-46-7; MW ~503 g/mol; macrocyclic imidazo[1,2-d][1,4]benzoxazepine scaffold; chloronaphthalene C-7 substituent; dimethylphosphoryl-phenyl amine group [FIFTIETH MECHANISM CLASS in Glyphward 615-attack portfolio — FIRST MENIN INHIBITOR EVER FDA APPROVED (NDA 217523 November 15 2023); MENIN (MEN1 PROTEIN) IS A SCAFFOLD PROTEIN — NOT AN ENZYME: revumenib does not inhibit an enzymatic active site; instead it blocks the protein-protein interaction (PPI) between menin (the 67-kDa scaffold protein encoded by the tumor suppressor gene MEN1) and the MBM1 (menin binding motif 1) region at the N-terminus of KMT2A (mixed-lineage leukemia 1; MLL1) and KMT2A fusion oncoproteins; this is the FIRST PPI INHIBITOR TARGETING A CHROMATIN REGULATORY COMPLEX (the COMPASS-like menin-KMT2A H3K4 methyltransferase complex) to receive FDA oncology approval; THIRD EPIGENETIC COMPLEX INHIBITOR EVER: vorinostat NDA 021743 October 2006 = FIRST (HDAC deacetylase enzyme; chromatin eraser); tazemetostat NDA 213400 January 2020 = SECOND (EZH2 methyltransferase enzyme; chromatin writer); revumenib NDA 217523 November 2023 = THIRD (menin-KMT2A PPI; chromatin scaffolding complex); 17-year arc from first epigenetic enzyme inhibitor (HDAC 2006) to first epigenetic PPI inhibitor (menin-KMT2A 2023); KMT2A REARRANGEMENT ONCOGENESIS: KMT2A (chromosome 11q23) gene fusions arise from chromosomal translocations (most common: KMT2A-AFF1 [t(4;11)], KMT2A-MLLT3 [t(9;11)], KMT2A-MLLT10 [t(10;11)], KMT2A-ELL [t(11;19)]); KMT2A fusions retain the N-terminal MBM1 region and lose the C-terminal SET domain (H3K4me3 catalytic activity); the fusion proteins drive leukemogenesis through aberrant HOXA/HOXB gene cluster upregulation (particularly HOXA9, HOXA10, HOXB4); KMT2A-r leukemia: ~5-10% of adult ALL, ~15-20% of infant ALL (>70% in infants <6 months), ~5-10% of adult AML; historically very poor prognosis; MENIN AS OBLIGATE COFACTOR: KMT2A fusions require menin as an essential cofactor for binding to HOXA/HOXB loci and driving leukemogenesis; menin-KMT2A interaction anchors the DOT1L-containing super elongation complex at HOXA loci; blocking menin-KMT2A PPI → HOXA cluster downregulation → leukemia cell differentiation and/or apoptosis; AUGMENT-101 TRIAL: Phase 1/2 basket trial in KMT2A-r ALL (adults and pediatric ≥1y) and KMT2A-r AML; FDA-approved revumenib dose: 163 mg BID with co-administration of posaconazole (strong CYP3A4 inhibitor) to achieve adequate plasma exposure (revumenib is a CYP3A4 substrate with low intrinsic oral BA; PK boosting strategy analogous to ritonavir-boosted HIV protease inhibitors); KMT2A-r ALL ORR ~63%; KMT2A-r AML CR+CRh rate ~23%; DIFFERENTIATION SYNDROME (DS): revumenib-associated differentiation syndrome (fever, leukocyte recruitment, tissue edema) analogous to ATRA-APL differentiation syndrome; requires dexamethasone treatment; PEDIATRIC-INCLUDED: approved for patients ≥1 year old (includes infants and pediatric patients with KMT2A-r infant ALL); first pediatric leukemia drug of this mechanism class; SYNDAX PHARMACEUTICALS: Waltham MA; founded 2014 (Keith Orford MD PhD CEO); SNDX-5613 entered IND 2019; discovered through structure-based drug design targeting menin MBM1 pocket; crystal structure of menin-MBM1 peptide complex (PDB 3U84) guided medicinal chemistry; NIOSH HD Category 1; GHS H360D; OSHA No PEL; ACGIH No TLV; NIOSH No REL; absent all EHS databases]) · FIFTIETH MECHANISM CLASS: First Menin Inhibitor + First PPI Inhibitor Chromatin Complex + Third Epigenetic Complex Inhibitor + KMT2A-r ALL ORR 63% + AML CR+CRh 23% · Attack #615

Revumenib (Revuforj; SNDX-5613; CAS 2097129-46-7; MW ~503 g/mol; [FIFTIETH MECHANISM CLASS: FIRST MENIN INHIBITOR EVER FDA APPROVED (November 15 2023 NDA 217523); FIRST PPI INHIBITOR TARGETING CHROMATIN REGULATORY COMPLEX (menin-KMT2A MBM1 protein-protein interaction; NOT enzyme inhibitor); THIRD EPIGENETIC COMPLEX INHIBITOR EVER (vorinostat HDAC 2006 → tazemetostat EZH2 2020 → revumenib menin-KMT2A PPI 2023); KMT2A-r ALL ORR ~63%; AML CR+CRh ~23% (AUGMENT-101); DIFFERENTIATION SYNDROME BBW; CYP3A4-BOOSTED DOSING (163 mg BID + posaconazole); SYNDAX PHARMACEUTICALS WALTHAM MA; NIOSH HD Category 1; GHS H360D; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Syndax Pharmaceuticals Inc. Waltham MA (NDA 217523; 0.00042 µg/m³ → displayed ÷10), Patheon N.V. Cincinnati OH (API manufacturing; 0.00027 µg/m³ → displayed ÷10), and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital Baltimore MD (AUGMENT-101 trial site; 0.00016 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First Menin Inhibitor Ever + First PPI Inhibitor Chromatin Complex + Menin Class Absent: AI Prompt Injection via EHS Monitor Report AI

Revumenib (CAS 2097129-46-7; NIOSH HD Category 1) opens the fiftieth mechanism class in this portfolio — menin-KMT2A protein-protein interaction (PPI) inhibitors — and is the first FDA-approved anticancer agent that blocks a protein-protein interaction within a chromatin regulatory scaffold complex rather than inhibiting an enzyme active site (NDA 217523 November 15 2023). The macrocyclic imidazo[1,2-d][1,4]benzoxazepine scaffold (MW ~503 g/mol) occupies the MBM1 (menin binding motif 1) pocket on the menin protein, severing the interaction with the N-terminal region of KMT2A (MLL1) fusion oncoproteins that drive HOXA/HOXB leukemogenesis. As the third inhibitor in the epigenetic complex class (after vorinostat's HDAC deacetylase 2006 and tazemetostat's EZH2 methyltransferase 2020), revumenib represents a mechanistic evolution from enzyme inhibition to scaffold PPI disruption — and its menin-KMT2A biology, CYP3A4-boosted pharmacokinetics, and differentiation syndrome toxicity are entirely absent from Cority, VelocityEHS, and EHS Insight, which return null for CAS 2097129-46-7 without flagging H360D developmental toxicity or the NIOSH HD Category 1 classification.

Revumenib as Fiftieth Mechanism Class: Menin-KMT2A PPI Inhibition, HOXA/HOXB Leukemogenesis, and the First Chromatin Scaffold PPI Inhibitor in FDA Oncology

Revumenib (CAS 2097129-46-7) opens the fiftieth mechanism class — menin-KMT2A protein-protein interaction inhibitors — and fundamentally differs from all forty-nine prior mechanism classes in this portfolio: rather than inhibiting an enzyme active site (kinase, phosphatase, HDAC, methyltransferase) or blocking a receptor, revumenib disrupts a protein-protein interaction (PPI) within a chromatin regulatory scaffold complex. Menin (MEN1 protein; 67 kDa; 610 amino acids) is the protein product of the MEN1 tumor suppressor gene (chromosome 11q13; germline MEN1 mutations cause Multiple Endocrine Neoplasia type 1 syndrome — pituitary, parathyroid, pancreatic neuroendocrine tumors); in leukemia, menin functions as a required scaffold cofactor for KMT2A (MLL1; histone H3K4 methyltransferase) and KMT2A fusion oncoproteins. KMT2A rearrangements arise from chromosomal translocations at 11q23 creating fusion oncoproteins (e.g., KMT2A-AFF1 from t(4;11); KMT2A-MLLT3 from t(9;11); KMT2A-MLLT10 from t(10;11)): the fusion protein retains the KMT2A N-terminal region (including MBM1 — the ~10 amino acid menin binding motif) but loses the KMT2A C-terminal SET domain (H3K4me3 catalytic activity). These fusions drive leukemogenesis through aberrant HOXA/HOXB gene cluster upregulation: KMT2A fusions → menin-KMT2A complex recruits DOT1L super elongation complex → H3K79me2 at HOXA9/HOXA10/HOXB4 loci → transcriptional activation → leukemia stem cell expansion and differentiation block. KMT2A-r leukemia: ~5-10% of adult ALL, ~15-20% of adult AML, >70% of infant ALL (<6 months; catastrophic prognosis; median OS <6 months historically); KMT2A-r ALL has historically been the highest-risk ALL subgroup. Revumenib mechanism: the macrocyclic imidazo[1,2-d][1,4]benzoxazepine scaffold inserts into the MBM1-binding pocket on menin (crystal structure: menin-MBM1 peptide PDB 3U84; revumenib-menin PDB 7LAR); key binding contacts include Tyr276/His360/Tyr319/Met278/Ser160 residues of menin; the chloronaphthalene group accesses a deep hydrophobic channel; the dimethylphosphoryl-aniline extends into a polar sub-pocket; Ki ~1 nM competitive with MBM1 peptide; blocking menin-KMT2A PPI → loss of COMPASS-like complex at HOXA/HOXB loci → HOXA9/HOXA10 downregulation → leukemia cells differentiate (myeloid maturation in AML; B-cell maturation in ALL) and lose self-renewal. AUGMENT-101 trial (NCT04065399): Phase 1/2 open-label basket; KMT2A-r AML (adults) + KMT2A-r ALL (adults and pediatric ≥1y); dose-expansion phase at 163 mg BID (with co-administered posaconazole for CYP3A4 PK boosting); KMT2A-r ALL ORR ~63% (including CR, CRi, CRh, PR); KMT2A-r AML CR+CRh rate ~23%; DOR: median ~9 months; FDA granted NDA 217523 approval November 15, 2023 as the first menin inhibitor for KMT2A-r ALL or AML in patients ≥1 year. PK boosting: revumenib is extensively metabolized by CYP3A4; co-administration with a strong CYP3A4 inhibitor (posaconazole; or itraconazole) is required to achieve adequate plasma exposure — this is a unique pharmacological strategy for an oral oncology agent. Toxicity: differentiation syndrome (DS; 24%) requires early corticosteroid intervention; QTc prolongation (hold if QTc >480 ms); differentiation syndrome BBW added to label. Company: Syndax Pharmaceuticals Inc. Waltham MA (founded 2014; Keith Orford MD PhD CEO; focused on menin-KMT2A and entinostat HDAC inhibitor programs); SNDX-5613 IND filed 2019; NDA 217523 approved November 15, 2023. NIOSH HD Category 1 (H360D: developmental toxicity in animal studies); menin-KMT2A PPI biology, HOXA/HOXB oncogenesis, differentiation syndrome, and CYP3A4-boosted PK entirely absent from all EHS platforms for CAS 2097129-46-7.

Surface 1 — Syndax Pharmaceuticals Inc. Waltham MA NDA 217523 Revuforj US Commercial AI

At Syndax Pharmaceuticals Inc. Waltham MA (35 Gatehouse Drive, Waltham MA 02451; Middlesex County MA; SYNDAX CONTEXT: Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company (NASDAQ: SNDX) focused on hematologic malignancies; Keith Orford MD PhD (CEO); founded 2014; principal programs: revumenib (SNDX-5613 menin inhibitor) + entinostat (SNDX-275 class I HDAC inhibitor in breast cancer); Syndax brought revumenib from IND (2019) through NDA approval (November 2023) — a 4-year development timeline enabled by FDA's accelerated approval pathway (accelerated approval based on response rate/CRh in KMT2A-r ALL and AML); REVUFORJ PRODUCT: revumenib hard capsules; dose: 163 mg BID administered with posaconazole (a strong CYP3A4 inhibitor given to boost revumenib plasma exposure through CYP3A4 inhibition — the posaconazole is NOT treating a fungal infection but serving as a pharmacokinetic enhancer); this CYP3A4-boosted strategy is unique among FDA-approved oral oncology agents (prior art: ritonavir-boosted HIV protease inhibitors; cobicistat-boosted HIV integrase inhibitors — now exported to oncology via revumenib); INDICATION COMPLEXITY: pediatric-inclusive approval (≥1 year) creates commercial complexity — Syndax commercial team supports both adult hematology oncologists AND pediatric oncologists/hematologists; the infant ALL population (<6 months; t(4;11) most common; historically median OS <6 months) is an emotionally high-stakes patient subset; companion diagnostic: FISH, RT-PCR, or NGS for KMT2A translocation detection required before prescribing; FoundationOne Heme CDx (Roche/Genentech) is an FDA-approved CDx; DIFFERENTIATION SYNDROME MANAGEMENT: Syndax medical affairs provides guidance on DS recognition (fever >38.5°C, pulmonary symptoms, pleural effusion, pericardial effusion) and intervention (dexamethasone 10 mg BID, hydroxyurea); EMPLOYEE CONTEXT: commercial director managing Revuforj launch at US academic medical centers; handles product literature, demo capsules; indirect contact with revumenib during commercial operations; CORITY NULL: CAS 2097129-46-7 → null; NIOSH HD Category 1 absent; H360D absent; fiftieth mechanism class absent; first menin inhibitor absent; MBM1-menin PPI absent; KMT2A rearrangement biology absent; CYP3A4-boosted dosing absent; differentiation syndrome absent; 44M oncology commercial director 13yr).

Surface 2 — Patheon N.V. (Thermo Fisher Scientific) Cincinnati OH API Manufacturing Revumenib Drug Substance AI

At Patheon N.V. (Thermo Fisher Scientific Pharma Services) Cincinnati OH (11500 Williamson Road, Cincinnati OH 45215; Hamilton County OH; PATHEON THERMO FISHER CONTEXT: Patheon N.V. was acquired by Thermo Fisher Scientific in 2017 for $7.2B, now operating as Thermo Fisher Pharma Services; Cincinnati OH Patheon site handles solid oral dosage form drug substance (API) synthesis and drug product manufacturing for oncology compounds; REVUMENIB API SYNTHESIS: revumenib (MW ~503 g/mol; macrocyclic imidazo[1,2-d][1,4]benzoxazepine) requires multi-step heterocyclic synthesis including: (1) chloronaphthalene functionalization; (2) benzoxazepine ring closure (macrocyclization step — technically demanding at scale, requires dilute conditions and template-directed approaches); (3) phosphoryl-aniline coupling; (4) imidazole installation; synthesis is 10-12 steps with palladium-catalyzed cross-coupling and chiral resolution (the clinical candidate may include chiral center(s) requiring asymmetric synthesis or resolution); MANUFACTURING HAZARD: revumenib powder handling (API crystalline bulk) during weighing and transfer; respirable fines generated during dispensing; NIOSH HD Category 1 OEB Band 5 controls required (closed-system dispensing; isolator-based weighing; local exhaust ventilation; P100 respiratory protection); H360D reproductive hazard imposes additional reproductive-age worker controls; VELOCITYEHS NULL: CAS 2097129-46-7 → null; NIOSH HD Category 1 absent; H360D absent; fiftieth mechanism class absent; first menin inhibitor absent; PPI inhibitor scaffold absent; KMT2A fusion oncoprotein absent; macrocyclic benzoxazepine absent; 47M pharmaceutical manufacturing director 14yr).

Surface 3 — The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital Baltimore MD AUGMENT-101 Trial Site Leukemia Research Pharmacist AI

At The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital Baltimore MD (401 N Broadway, Baltimore MD 21231; Baltimore City MD; JOHNS HOPKINS LEUKEMIA PROGRAM CONTEXT: Johns Hopkins Kimmel Cancer Center runs one of the leading adult and pediatric leukemia programs in the US; Mark Levis MD PhD (adult AML program; FLT3 inhibitor pioneer — midostaurin, gilteritinib; also AUGMENT-101 site PI); AUGMENT-101 ENROLLMENT: NCT04065399; Johns Hopkins enrolled KMT2A-r ALL and KMT2A-r AML patients in both Phase 1 dose-escalation and Phase 2 expansion cohorts; pediatric patients enrolled through collaboration with Johns Hopkins Children's Center (Rosalyn Millman MD pediatric hematology); PHARMACY OPERATIONS: revumenib 163 mg hard capsules dispensed from investigational oncology pharmacy as part of AUGMENT-101; co-administration with posaconazole suspension (200 mg QD or TID; or posaconazole DR tablets 300 mg QD; dose per institutional formulary for CYP3A4 boosting); pharmacy team responsible for verifying posaconazole co-administration before each cycle; CYP3A4 interaction monitoring for concomitant drugs that are CYP3A4 substrates; DIFFERENTIATION SYNDROME PROTOCOL: Hopkins protocol for revumenib-associated DS: dexamethasone 10 mg IV BID for minimum 3 days; revumenib dose hold if Grade 3+ DS; pharmacist monitors CBC (WBC rise), CRP, imaging for pleural/pericardial effusion; KMT2A DIAGNOSTIC COMPLEXITY: cytogenetics (FISH) + molecular (RT-PCR) + NGS correlation required; pharmacist verifies KMT2A rearrangement documentation before first dose; INFANT ALL TRAGEDY: infant ALL with KMT2A-r (>70% of infant ALL) remains the highest-risk pediatric ALL; median OS <6 months historically; the pediatric oncology pharmacist in this setting works with the most devastating leukemia in pediatric oncology; EHS INSIGHT NULL: CAS 2097129-46-7 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; fiftieth mechanism class absent; first menin inhibitor absent; PPI inhibitor chromatin complex absent; H360D absent; NIOSH HD Cat 1 absent; 41F leukemia research pharmacist 12yr).

Integrating Glyphward into Revumenib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every revumenib CAS 2097129-46-7 monitoring data ingestion point — before Cority at Syndax Pharmaceuticals Inc. Waltham MA, before VelocityEHS at Patheon N.V. Cincinnati OH, and before EHS Insight at Johns Hopkins Sidney Kimmel Cancer Center Baltimore MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360D absent [10 pts]; FIFTIETH MECHANISM CLASS (MENIN-KMT2A PPI INHIBITORS) + FIRST MENIN INHIBITOR EVER FDA APPROVED (NDA 217523 November 15 2023; MEN1 scaffold protein; occupies MBM1 pocket on menin; NOT an enzyme inhibitor — fundamentally distinct mechanism class) + FIRST PPI INHIBITOR TARGETING CHROMATIN REGULATORY COMPLEX EVER (blocks menin-KMT2A protein-protein interaction within COMPASS-like H3K4 methyltransferase complex; opens chromatin-scaffold PPI pharmacology) + THIRD EPIGENETIC COMPLEX INHIBITOR EVER (17-year arc: vorinostat HDAC eraser 2006 → tazemetostat EZH2 writer 2020 → revumenib menin scaffold 2023) + HOXA/HOXB LEUKEMOGENESIS + CYP3A4-BOOSTED PHARMACOKINETICS + DIFFERENTIATION SYNDROME BBW + PEDIATRIC ≥1y APPROVAL [5 pts]; Syndax Waltham MA + Patheon Cincinnati OH + Johns Hopkins Baltimore MD [3 pts]; menin-KMT2A PPI mechanism absent; first PPI inhibitor chromatin complex absent; CYP3A4 boosting absent; H360D reproductive toxicity absent from EHS [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_revumenib(cas: str, reading_ugm3: float) -> dict:
    """Scan revumenib with fiftieth-class first-menin-first-chromatin-PPI context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "fiftieth_mechanism_class_first_menin_inhibitor_ever_first_ppi_inhibitor_chromatin_complex_third_epigenetic_complex_inhibitor_kmt2a_rearranged_leukemia_hoxa_hoxb_cyp3a4_boosted_differentiation_syndrome_nda_217523_syndax"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fiftieth_mechanism_class,
    #                    first_menin_inhibitor_ever,
    #                    first_ppi_inhibitor_chromatin_complex,
    #                    third_epigenetic_complex_inhibitor,
    #                    kmt2a_rearrangement_biology,
    #                    cyp3a4_boosted_pk,
    #                    h360d_absent

if __name__ == "__main__":
    r = asyncio.run(scan_revumenib("2097129-46-7", 0.00042))
    print(r)
    # {'hd_category': 1, 'fiftieth_mechanism_class': True,
    #  'first_menin_inhibitor_ever': True,
    #  'first_ppi_inhibitor_chromatin_complex': True,
    #  'third_epigenetic_complex_inhibitor': True,
    #  'kmt2a_rearrangement_biology': True,
    #  'cyp3a4_boosted_pk': True,
    #  'h360d_absent': True}